Molecular therapy for Bone disorders: ASPP2 (Apoptosis-stimulating protein of Tp53-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 20/December/2016, 9.49 pm

Natural product-derived therapy for enhancing anti-cancer immunity: Hesperidin, found abundantly in Citrus fruits, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 20/December/2016, 6.27 pm
December 20, 2016
Anti-telomerase cancer therapy: MiR-204 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 16/December/2016, 9.57 pm
December 20, 2016
Show all

Introduction: What they say

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.


What we say:

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: ASPP2  (Apoptosis-stimulating protein of Tp53-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene


From Research findings to Therapeutic utility

ASPP2, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. 

price-50[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “ASPP2 activators or ASPP2 activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.


Details of the research findings

Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD

Undisclosed mechanistic information: How ASPP2 suppresses the expression of Tgif2

Amount: $50#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

#Research cooperation

For purchase & payment details, you may reach us at admin@genomediscovery.org


 References:

CitationBoominathan, L., Molecular therapy for Bone disorders: ASPP2 (Apoptosis-stimulating protein of Tp53-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 20/December/2016, 9.49 pm., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.